Center InformationBarbara Bradshaw, General Manager AMR Kansas City 1010 Carondelet Drive, Suite #426 Kansas City, MO 64114 Phone: 816-943-0770 Fax: 816-942-3195 Email: email@example.com www.cprkc.com
Currently Enrolling Trials
AMR Kansas City (formerly Center for Pharmaceutical Research) is a dedicated clinical research center specializing in Phase 1, 2, 3 and 4 clinical trials for the pharmaceutical, nutraceutical and medical device industries.
AMRKC has two primary missions, each equally important: to provide ethical, safe, cutting-edge medical care for our volunteers and high-quality, clean data to our sponsors with strict adherence to GCP guidelines.
John E. Ervin, MD, FACP, FACR, founded The Center for Pharmaceutical Research in 1986 and serves as the president, medical director and principal investigator. The Center for Pharmaceutical Research was audited by the FDA in 1995, 2010 and 2016 with no findings and no 483s issued. Since its inception, AMR Kansas City has conducted more than 800 trials in most areas of multispecialty research including:
- Acid Reflux
- Alzheimer’s Disease
- Bio-Terrorism Vaccines
- Diabetic Neuropathy
- Erectile Dysfunction
- Female Sexual Dysfunction
- Genital Herpes
- Healthy Volunteers
- High Cholesterol
- Irritable Bowel
- Men’s Health
- Oral Contraceptive
- Postherpetic Neuralgia
- Premature Ejaculation
- Rheumatoid Arthritis
- Sleep Disorders
- Smoking Cessation
- Ulcerative Colitis
- Women’s Health
Dr. Ervin received his medical degree from the University of Kansas School of Medicine. There, he completed a residency in internal medicine and a fellowship in allergy, immunology and rheumatology. He is board-certified in both internal medicine and rheumatology and is ISCD-certified in bone densitometry. Dr. Ervin’s professional credentials include:
- Founding member and current president of The Alliance for Multispecialty Research;
- Past president of the Society of Principal Investigators; and
- Member of the American Academy of Pharmaceutical Physicians and Investigators.
At AMRKC, we realize that our subjects are volunteers and we treat them as honored guests. In an exit survey, our subjects indicate over 95 percent satisfaction with their previous studies and more than 90 percent request to be considered for future studies. Our coordinators take time to know their subjects personally. As a result, volunteer retention is extremely high and previous participants refer many of our new study volunteers.
Our recruitment and enrollment team develops a recruitment plan for each study and pre-screens subjects by phone. Our staff expertise ensures efficient, effective use of the sponsor’s recruitment investment. As a result, AMRKC consistently over-enrolls in trials for patient populations, including infants, pediatrics, adults and geriatrics.